RxDoctor Payments Data

Alberto Sanchez, MD

Internal Medicine · Crown Point, INNPI 1659376259

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 88 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$285
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$215
  • AbbVie$198
  • Novo Nordisk$86
  • Sanofi-aventis U.S. LLC$78
  • AMAG Pharmaceuticals, Inc.$66
  • plus $437 from 16 others

What the payments were for

  • Food & beverage$1,25392%
  • Education$1118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,365 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$89,345
Medicare patients
264
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$116,399
EliquisApixaban87$74,166
MounjaroTirzepatide27$45,777
JanuviaSitagliptin Phosphate47$40,995
JardianceEmpagliflozin39$39,892
XareltoRivaroxaban34$39,683
FarxigaDapagliflozin Propanediol37$35,605
Breo ElliptaFluticasone/Vilanterol57$22,143
EntrestoSacubitril/Valsartan20$18,738
RybelsusSemaglutide13$12,390
Tresiba Flextouch U-100Insulin Degludec17$11,327
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen409$9,601
Repatha SureclickEvolocumab15$8,169
Incruse ElliptaUmeclidinium Bromide15$7,802
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$6,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$86$128,789105 claims
PfizerEliquis$11$74,16687 claims
Lilly USA, LLCMounjaro$58$45,77727 claims
Boehringer IngelheimJardiance$24$39,89239 claims
Johnson & JohnsonXarelto$27$39,68334 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta$41$36,83388 claims
AstraZenecaFarxiga$285$35,60537 claims
NovartisEntresto$12$18,73820 claims
AbbVieSynthroid$198$1,41225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Crown Point

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →